Idioma:

Updates on DNA methylation modifiers in acute myeloid leukemia

Contieri, Bruna ; Duarte, Bruno Kosa Lino ; Lazarini, Mariana

Annals of hematology, 2020-04, Vol.99 (4), p.693-701 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por

Enviar para

Título:
Updates on DNA methylation modifiers in acute myeloid leukemia
Autor: Contieri, Bruna ; Duarte, Bruno Kosa Lino ; Lazarini, Mariana
Assuntos: Aged ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Azacitidine - administration & dosage ; Azacitidine - pharmacology ; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage ; Chemotherapy ; Clinical Trials as Topic ; Decitabine - administration & dosage ; Decitabine - pharmacology ; DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors ; DNA methylation ; DNA Methylation - drug effects ; DNA, Neoplasm - drug effects ; DNA, Neoplasm - metabolism ; Enzyme Inhibitors - therapeutic use ; FDA approval ; Hematology ; Humans ; Isocitrate Dehydrogenase - antagonists & inhibitors ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - metabolism ; Medicine ; Medicine & Public Health ; Meta-Analysis as Topic ; Molecular Targeted Therapy ; Multicenter Studies as Topic ; Neoplasm Proteins - antagonists & inhibitors ; Neoplasm Proteins - genetics ; Oncology ; Review Article ; Sulfonamides - administration & dosage ; Treatment Outcome
É parte de: Annals of hematology, 2020-04, Vol.99 (4), p.693-701
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Chemotherapy with cytotoxic agents is the standard of care, but is associated with a high rate of adverse events. Elderly patients are frequently intolerant to such treatment, presenting a very poor prognosis. The hypomethylating agents (HMA) azacitidine or decitabine represent one of the main therapeutic alternatives for these patients. Isocitrate dehydrogenase inhibitors (IDH) constitute another therapeutic class with DNA methylation effects in AML. In this article, we review the use of first- and second-generation HMA and IDH inhibitors in AML. The data collected demonstrated that HMA are generally considered effective and safe for AML patients who are not eligible for standard chemotherapy. The combination of azacitidine or decitabine with venetoclax was recently approved by the US Food and Drug Administration (FDA) for older AML patients and those unfit for intense chemotherapy. IDH inhibitors also showed encouraging results for relapsed/refractory AML patients harboring an IDH mutation and received FDA approval. Therefore, recent studies have led to the emergence of new therapeutic options using HMA and IDH inhibitors for specific groups of AML patients, representing an important step in the treatment of this aggressive malignancy. New options should emerge from the ongoing studies in the coming years.
Editor: Berlin/Heidelberg: Springer Berlin Heidelberg
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Updates on DNA methylation modifiers in acute myeloid leukemia

Contieri, Bruna ; Duarte, Bruno Kosa Lino ; Lazarini, Mariana

Berlin/Heidelberg: Springer Berlin Heidelberg

Buscando em bases de dados remotas. Favor aguardar.